Azzimonti M, Preziosa P, Pagani E, Meani A, Margoni M, Rubin M
J Neurol. 2025; 272(3):228.
PMID: 39998642
DOI: 10.1007/s00415-025-12979-4.
Szekely-Kohn A, Castellani M, M Espino D, Baronti L, Ahmed Z, Manifold W
R Soc Open Sci. 2025; 12(1):241052.
PMID: 39845718
PMC: 11750376.
DOI: 10.1098/rsos.241052.
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A
Int J Mol Sci. 2024; 25(16).
PMID: 39201438
PMC: 11354232.
DOI: 10.3390/ijms25168751.
El Ayoubi N, Ismail A, Fahd F, Younes L, Chakra N, Khoury S
Ann Clin Transl Neurol. 2024; 11(9):2236-2253.
PMID: 39073308
PMC: 11537126.
DOI: 10.1002/acn3.52165.
Ananthavarathan P, Sahi N, Chung K, Haider L, Prados F, Trip S
J Neurol Neurosurg Psychiatry. 2024; .
PMID: 39038948
PMC: 7616528.
DOI: 10.1136/jnnp-2024-333917.
Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
Molenaar P, Noteboom S, van Nederpelt D, Krijnen E, Jelgerhuis J, Lam K
J Neurol. 2024; 271(9):5958-5968.
PMID: 39008036
PMC: 11377687.
DOI: 10.1007/s00415-024-12516-9.
Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing.
Tan I, Modderman R, Stachurska A, Almeida R, de Vries R, Heersema D
Brain Commun. 2024; 6(4):fcae209.
PMID: 38978729
PMC: 11229703.
DOI: 10.1093/braincomms/fcae209.
Breaking boundaries: the transformative role of exercise in managing multiple sclerosis.
Saedmocheshi S, Yousfi N, Chamari K
EXCLI J. 2024; 23:475-490.
PMID: 38741722
PMC: 11089092.
DOI: 10.17179/excli2024-6932.
Lifestyle management and brain MRI metrics in female Australian adults living with multiple sclerosis: a feasibility and acceptability study.
Wills O, Wright B, Greenwood L, Solowij N, Schira M, Maller J
Pilot Feasibility Stud. 2024; 10(1):71.
PMID: 38698454
PMC: 11064336.
DOI: 10.1186/s40814-024-01495-3.
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients.
Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Di Caprio V
Front Neurol. 2024; 15:1326506.
PMID: 38585351
PMC: 10995923.
DOI: 10.3389/fneur.2024.1326506.
Radiologically isolated syndromes: to treat or not to treat?.
Preziosa P, Rocca M, Filippi M
J Neurol. 2024; 271(5):2370-2378.
PMID: 38502339
DOI: 10.1007/s00415-024-12294-4.
Evaluation of the quality and the productivity of neuroradiological reading of multiple sclerosis follow-up MRI scans using an intelligent automation software.
Federau C, Hainc N, Edjlali M, Zhu G, Mastilovic M, Nierobisch N
Neuroradiology. 2024; 66(3):361-369.
PMID: 38265684
PMC: 10859335.
DOI: 10.1007/s00234-024-03293-3.
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
Mattiesing R, Kramer E, Strijbis E, Brouwer I, van Schijndel R, Gentile G
Mult Scler. 2023; 30(1):44-54.
PMID: 38018502
PMC: 10782656.
DOI: 10.1177/13524585231212879.
A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach.
Bunul S, Alagoz A, Cinar B, Bunul F, Erdogan S, Efendi H
J Pers Med. 2023; 13(11).
PMID: 38003852
PMC: 10672718.
DOI: 10.3390/jpm13111537.
CD8+ T cells recognizing a neuron-restricted antigen injure axons in a model of multiple sclerosis.
Clarkson B, Grund E, Standiford M, Mirchia K, Westphal M, Muschler L
J Clin Invest. 2023; 133(21).
PMID: 37676734
PMC: 10617772.
DOI: 10.1172/JCI162788.
Diagnostic Potential of Two Novel Biomarkers for Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.
Xu T, Shi Y, Zheng G, Zhang G
Diagnostics (Basel). 2023; 13(9).
PMID: 37174963
PMC: 10178292.
DOI: 10.3390/diagnostics13091572.
Repair what is lost: Neuroprotection through neural stem cells in progressive MS.
Schoonheim M, Strijbis E
Cell Rep Med. 2023; 4(3):100985.
PMID: 36948155
PMC: 10040451.
DOI: 10.1016/j.xcrm.2023.100985.
Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.
Lorefice L, Pitzalis M, Murgia F, Fenu G, Atzori L, Cocco E
Front Genet. 2023; 14:1076421.
PMID: 36793897
PMC: 9922720.
DOI: 10.3389/fgene.2023.1076421.
Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis.
Fiore A, Preziosa P, Tedone N, Margoni M, Vizzino C, Mistri D
Mol Psychiatry. 2023; 28(4):1770-1782.
PMID: 36658334
DOI: 10.1038/s41380-023-01943-1.
Potentially toxic elements in the brains of people with multiple sclerosis.
Pamphlett R, Buckland M, Bishop D
Sci Rep. 2023; 13(1):655.
PMID: 36635465
PMC: 9837144.
DOI: 10.1038/s41598-022-27169-9.